Skip to content
DataLookout
Menu

NCT05231785

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 52 versions: 17 with changes below, 33 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Site details revised at 1 of 8 sites
  2. Notable Eligibility criteria expanded, about 7 words
    • Primary and study completion moved earlier from Apr 20, 2029 to Jan 11, 2029
    • Secondary endpoints: details revised at 1 of 5 entries
  3. Minor Primary and study completion dates: Mar 28, 2029 to Apr 20, 2029
    • Site details revised at 4 of 8 sites
    v43
  4. Minor Site details revised at 8 of 8 sitesv42
  5. Notable Primary and study completion dates pushed to Mar 28, 2029v37
Show 12 earlier versionsHide 12 earlier versions
  1. Minor Study completion date: Jul 1, 2027 to Mar 1, 2029v34
  2. Minor Site details revised at 1 of 8 sitesv32
  3. Minor Study sites: 7 to 8v29
  4. Minor Primary completion date: Jul 2025 to Jul 1, 2025
    • Study completion date: Jul 2027 to Jul 1, 2027
    v27
  5. Notable Eligibility criteria expanded, about 9 words
    • Study sites: 5 to 7
    • Study completion date: Jul 2025 to Jul 2027
    • Secondary endpoints revised (5)
    v25
  6. Minor Study sites: 6 to 5v24
  7. Minor Study sites: 7 to 6v22
  8. Minor Study sites: 6 to 7v18
  9. Minor Site details revised at 2 of 6 sitesv15
  10. Minor Study sites: 4 to 6v12
  11. Minor Study sites: 2 to 4v8
  12. Minor Study sites: 1 to 2v6
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Part A: Frequency of Adverse Events
Timeframe: Up to 12 months
Part B: Frequency of Adverse Events
Timeframe: Up to 42 months

Secondary (5)

Part A and Part B: Change from Baseline in Levels of Cerebrospinal Fluid (CSF) Soluble Amyloid Precursor Protein Alpha (sAPPα) and Soluble Amyloid Precursor Protein Beta (sAPPβ)
Part A and Part B: Area Under the Plasma Concentration-time Curve (AUC) of ALN-APP and of Potential Metabolites
Part A and Part B: Maximum Observed Plasma Concentration (Cmax) of ALN-APP and of Potential Metabolites
Part A: Fraction of ALN-APP and Potential Metabolites Excreted in the Urine (fe)
Part A and Part B: Concentration of ALN-APP and Potential Metabolites at Time 't' (Ct) in Plasma and CSF

Arms and interventions

Part A: ALN-APPExperimental

Participants will be administered a single dose of ALN-APP.

Part A: PlaceboPlacebo comparator

Participants will be administered a single dose of placebo.

Part B:Experimental

Participants will be administered multiple doses of ALN-APP.

Drugs: ALN-APP, Placebo

Sites

8 sites in 4 countries

Canada 2, Netherlands 2, United Kingdom 2, United States 2